All In Biotech

Drug Trial Radar · NCT03835949

Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer

A Phase 1 Dose-Escalation Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer

Last checked: Nov 19, 2026Latest source record: Apr 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

36

Planned (sponsor's estimate)

Start

Jul 16, 2019

Primary completion

Jun 2022

Study completion Jun 2022

Sponsor

Lead sponsor
Tracon Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Feb 11, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open label, Phase 1 dose escalation study of TJ004309 in combination with standard dose atezolizumab in patients with advanced or metastatic cancer in patients who are refractory to or intolerant to all available therapy.

Conditions

  • Solid Tumor
  • Metastatic Cancer

Interventions

  • TJ004309Drug

    Antibody to CD73

  • AtezolizumabDrug

    Humanized monoclonal antibody to PD-L1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerate Dose of TJ004309 plus AtezolizumabTime frame: Approximately 2-8 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • The University of Alabama at Birmingham

    Birmingham, Alabama

  • HonorHealth Research Institute

    Scottsdale, Arizona

  • City of Hope

    Duarte, California

  • MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.